Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to sign informed consent
- Have HER2-negative breast cancer that has spread (metastatic) and was confirmed by biopsy, with ER/PR/HER2 testing on that sample
- Your tumor must be AR-positive (androgen receptor–positive), meaning at least 1% staining on a lab test of the metastatic tumor
- Have measurable or assessable disease on scans (CT chest/abdomen/pelvis with bone scan or PET/CT)
- If you are ER+ or PR+, you must have had at least 1 prior hormone (endocrine) treatment for metastatic disease; if triple-negative, prior chemotherapy limits apply
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This trial tests if adding abemaciclib (a targeted pill) to standard chemotherapy before surgery can shrink HR+/HER2- breast cancer and allow less extensive surgery. It also aims to see if a genetic test (Oncotype DX) can help guide treatment decisions.
This trial tests whether the drug abemaciclib can help women with hormone receptor-positive, HER2-negative breast cancer who still have signs of cancer DNA in their blood after standard treatment. It aims to prevent a future return of the cancer.
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.